Botox for migraines: waste, high cost, and low adherence

Botox® is not much help either 

August 21, 2019

Finding the right treatment can be a real headache for migraine patients; for those who finally try it, it doesn’t look like Botox® is much help either

Patients who try Botox have not responded to other conventional migraine therapies. They have struggled to find relief from acute, debilitating headaches. This study looked at 2,500 patients who were new to Botox therapy. Treatment consists of injections given in the face, head and neck by a doctor in a health care setting.

Waste: Because of vial sizes and dosing, there is substantial drug waste. Drug waste and provider administration accounts for one-third of the drug’s $6,300 annual cost. Low adherence: Less than half of the patients completed the recommended four courses of quarterly treatments. This indicates treatment failure. High cost: The study found that Botox did not decrease total cost of care for patients with migraines. It was associated with a three-fold increase in total migraine-related costs.

Read more

OnabotulinumToxinA (Botox® ) and Migraine: Persistence, Utilization and Expenditure within the Botulinum Toxin Drug Class (Fall 2019)

Related news

Perspectives

May 1, 2024

Prime Therapeutics releases new clinical insights report, “Weight management: A holistic journey”

Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss

Perspectives

April 30, 2024

AMCP 2024: Behind the GLP-1 Spotlight Session with Ben Urick

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Perspectives

April 30, 2024

Quarterly Drug Pipeline

Clinical insights and competitive intelligence on anticipated drugs in development